Stefanie Urlinger

Stefanie Urlinger is Chief Scientific Officer at Cimeio Therapeutics, where she heads Research and Discovery. Stefanie has over 20 years of experience in large molecule engineering and development and has led antibody discovery efforts as well as the development of antibody platform technologies in different organizations, including MorphoSys, iOmx Therapeutics and Ridgeline Discovery. Stefanie has authored many scientific articles and is an inventor on over 60 granted patents. Stefanie earned her PhD from the Max-Planck-Institute for Biochemistry in Germany.